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Abstract
Background: We previously reported that the immunogenicity of Hcbtre, a botulinum neurotoxin A (BoNT/A) immunogen,
was enhanced by fusion to an epithelial cell binding domain, Ad2F, when nasally delivered to mice with cholera toxin (CT).
This study was performed to determine if Ad2F would enhance the nasal immunogenicity of Hcbtre in rabbits, an animal
model with a nasal cavity anatomy similar to humans. Since CT is not safe for human use, we also tested the adjuvant
activity of compound 48/80 (C48/80), a mast cell activating compound previously determined to safely exhibit nasal
adjuvant activity in mice.
Methods: New Zealand White or Dutch Belted rabbits were nasally immunized with Hcbtre or Hcbtre-Ad2F alone or
combined with CT or C48/80, and serum samples were tested for the presence of Hcbtre-specific binding (ELISA) or BoNT/A
neutralizing antibodies.
Results: Hcbtre-Ad2F nasally administered with CT induced serum anti-Hcbtre IgG ELISA and BoNT/A neutralizing antibody
titers greater than those induced by Hcbtre + CT. C48/80 provided significant nasal adjuvant activity and induced BoNT/A-
neutralizing antibodies similar to those induced by CT.
Conclusions: Ad2F enhanced the nasal immunogenicity of Hcbtre, and the mast cell activator C48/80 was an effective
adjuvant for nasal immunization in rabbits, an animal model with a nasal cavity anatomy similar to that in humans.
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Introduction
Clostridium botulinum is a spore-forming anaerobe which produces
seven distinct neurotoxin serotypes (A–G). Botulinum neurotoxin
is synthesized as a 150 kDa single chain protein and cleaved by
proteases to yield a 100 kDa heavy chain (Hc) linked by a disulfide
bridge to a 50 kDa light chain (Lc) [1,2] (Figure 1). The Hc
encompasses the neuronal cell binding b-trefoil domain [3] and
membrane translocation units, and the Lc cleaves SNARE
proteins, required for the release of acetylcholine at the
neuromuscular junction. The botulinum neurotoxins (BoNT),
combined with tetanus neurotoxin, comprise the class of clostridial
neurotoxins. Clostridial neurotoxins are the most poisonous
natural substances known to man; oral consumption of as little
as 7 mg or inhalation of 700 ng is predicted to be lethal to a 150 lb
individual [4].
A toxoid vaccine composed of formalin inactivated botulinum
neurotoxin has been used as the botulinum neurotoxin vaccine for
decades [5,6]. The declining immunogenicity of the toxoid vaccine
and the availability of molecular biology techniques to produce
non-toxic subunit immunogens has lead to the development of
next generation botulinum vaccines that are based on recombi-
nant fragments of the heavy chain [5]. A recombinant botulinum
vaccine based on the cell binding domain (Hc) is currently being
tested in human clinical trials (http://clinicaltrials.gov and [5]).
We previously reported that a recombinant immunogen
containing botulinum neurotoxin type A (BoNT/A) Hc b-trefoil
domain (Hcbtre) induced complete protection against a 20,000
LD50 BoNT/A challenge in mice when used as a nasal vaccine
immunogen coadministered with cholera toxin as a mucosal
adjuvant [7]. Additionally, production of a fusion protein
immunogen that contained the Hcbtre fused to the adenovirus
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exhibited superior immunogenicity when compared to the Hcbtre
subunit immunogen after nasal (or parenteral) immunization of
mice while also inducing complete protection against a 20,000
LD50 BoNT/A challenge [7].
Although our previous study demonstrated the protective
capacity of the Hcbtre and Hcbtre-Ad2F immunogens when
delivered nasally to mice, the use of a mouse model may not be
ideal when evaluating immunogens for nasal delivery to humans.
For example, the mouse nasal cavity is organized to have
organized nasal-associated lymphoid tissue (NALT) in the floor
of the nasal cavity [8–12] while the NALT tissues in larger animals
such as rabbits, non-human primates and humans, likely includes
immune tissues distributed throughout the nasal cavity [13,14] as
well as the tonsils, adenoids and Waldeyer’s ring [15,16].
Therefore, evaluation of nasal vaccines in rabbits, animals that
have a nasal cavity immune system more closely related to
humans, may be an ideal animal model to evaluate the
immunogenicity of vaccines proposed for nasal vaccination of
humans.
Most recombinant protein vaccines lack sufficient immunoge-
nicity and must be formulated with adjuvants to induce maximal
protective immunity. We have recently reported that a novel class of
vaccine adjuvants, mast cell activators, provided safe and effective
vaccine adjuvant activity when delivered nasally [17] or intrader-
mally [18] to mice. Although cholera toxin and the related labile
toxin provide potent mucosal vaccine adjuvant activity, their
numerous adverse effects (induction of IgE, lethal anaphylaxis,
pulmonary inflammation, diarrhea, accumulation in olfactory
tissues and Bell’s Palsy [19–25]) will likely prevent their use in
humans. Therefore, adjuvants that provide safe and effective
adjuvant activity when delivered by a mucosal route are needed for
development of mucosally-administered vaccines for human use.
In this study we evaluated our novel botulinum neurotoxin
immunogens, Hcbtre and Hcbtre-Ad2F, for their ability to induce
BoNT/A-neutralizing antibodies when nasally delivered to
rabbits, a species whose nasal structure more closely resembles
humans. Additionally, we evaluated a novel vaccine adjuvant, the
mast cell activator compound 48/80 (C48/80), for its ability to
enhance the immunogenicity of nasally-delivered BoNT/A
subunit immunogens in rabbits. Our results demonstrate that
Hcbtre-Ad2F is superior to Hcbtre for the induction of BoNT/A
neutralizing antibodies after nasal delivery with adjuvant and that
the mast cell activator C48/80 provides effective adjuvant activity
for nasally-administered vaccines in rabbits.
Materials and Methods
Ethics Statement
All animal research was performed using Duke University
Institutional Animal Care and Use Committee (IACUC) approved
procedures under protocols A256-06-07 and A181-09-06.
Mice and rabbits
Female BALB/c mice (Charles River/NCI) were used to
perform the serum BoNT/A neutralization assay. New Zealand
White (females) and Dutch Belted (females) rabbits were obtained
from RSI Biotechnology (Mocksville, NC).
Recombinant protein expression and purification
Recombinant botulinum neurotoxin type A b-trefoil (Hcbtre)
and the fusion protein containing Hcbtre linked to the adenovirus
type 2 fiber protein (Hcbtre-Ad2F) were produced as described
previously [7]. Briefly, a synthetic gene encoding Hc BoNT/A,
amino acids K1076 to L1295 (GenBank accession no. X52066),
was designed for expression in the yeast, Pichia pastoris, and cloned
into the P. pastoris expression vector, pPICZ B. To produce
Hcbtre-Ad2F, the C-terminal region of adenovirus 2 fiber protein,
spanning amino acids G378 to E582 was cloned from genomic
adenovirus 2 DNA and fused to the Hcbtre plasmid. Recombinant
Figure 1. Schematic representation of Hcbtre-Ad2F fusion protein. A. schematic representation of botulinum neurotoxin type A (heavy and
light chains). B. Schematic of b-trefoil domain of BoNT/A heavy chain (Hcbtre). C. Schematic of fusion protein containing b-trefoil domain of BoNT/A
heavy chain (Hcbtre) and the adenovirus type 2 fiber protein (Hcbtre-Ad2F).
doi:10.1371/journal.pone.0016532.g001
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cleared by centrifugation, filtered through a 1.2 mm prefilter and
then through a 0.45 mm filter under vacuum. Cleared superna-
tants were applied to a Talon column (BD Biosciences, San Jose,
CA), as per manufacturer’s instruction. Purified proteins were
eluted and titrated. Their quality was assessed by SDS-PAGE and
Coomassie staining.
Immunizations and sample collection
Azide-free cholera toxin (CT) was purchased from List
Biological Laboratories (Campbell, CA). Compound 48/80
(C48/80) and alum were purchased from SIGMA (St. Louis,
MO). Botulinum neurotoxin A (BoNT/A) toxoid and heavy chain
(Hc) were purchased from Metabiologics (Madison, WI). New
Zealand White female rabbits were sedated with acepromazine
(1 mg/kg) and anesthetized with isoflurane (4% isoflurane at 4
liters/minute oxygen) before intranasal immunization on days 0,
14 and 28 with equimolar doses of BoNT/A Hcbtre (10 mg) or
BoNT/A Hcbtre-Ad2F (20 mg) alone or combined with the
adjuvants, CT (2 mg) or C48/80 (120 mg). The nasal vaccine
formulation was prepared to a total volume of 250 ml with 125 ml
delivered to each nostril. Rabbits were held on their backs for
nasal immunization and maintained on their backs for approxi-
mately 30 seconds after nasal delivery before being returned to
their cage. Rabbits were upright and conscious, although sedated,
after being returned to their cage. For the alum control groups,
awake rabbits were immunized intramuscularly (100 ml) with
BoNT/A toxoid (10 mg) formulated with alum (350 mg) on days 0,
14 and 28. Serum was collected on days 0, 27 and 40. Dutch
Belted female rabbits were sedated with acepromazine (1 mg/kg)
and anesthetized with isoflurane (4% isoflurane at 4 liters/minute
oxygen) before intranasal immunization on days 0, 14, 28 and 91
with equimolar doses of BoNT/A Hcbtre (10 mg) or BoNT/A
Hcbtre-Ad2F (20 mg) alone or combined with the adjuvants, CT (2
mg) or C48/80 (120 mg). The nasal vaccine formulation for Dutch
Belted rabbits was prepared to a total volume of 200 ml with
100 ml delivered to each nostril. Serum samples were collected
days 0, 27, 41, 105 and 162. Vaginal lavage and fecal samples
were collected on days 0 and 105.
ELISA detection of antibodies specific for BoNT/A Toxoid,
Hc and b-trefoil
Sera were tested for the presence of antigen-specific IgG
antibodies using an ELISA protocol that utilizes the fluorescent
substrate Attophos (Promega, Madison, WI) as previously reported
by our group using log2 serum dilutions beginning at 1:32 (1:2
5)
[18,26–28] except that the coating antigens consisted of BoNT/A
toxoid, Hc or Hcbtre. Antigen-specific IgG antibodies were
detected with goat anti-rabbit IgG-alkaline phosphatase (Southern
Biotech, Birmingham, AL). Endpoint titers were defined as the
highest reciprocal dilution of sample giving a fluorescence value 3-
fold over an equally diluted naı ¨ve sample from the same animal.
Log2 titers were used for statistical analysis. Samples with no
detectable antibody were assigned a value 1 less than the starting
log2 dilution for statistical analysis.
Avidity ELISA
A modified ELISA assay was utilized to estimate the avidity of
vaccine-induced anti-BoNT/A antibodies using a protocol de-
scribed by others [29–31] with slight modifications. Day 162
serum collected from immunized Dutch Belted rabbits was diluted
so that each sample produced a similar raw data anti-BoNT/A
Hcbtre ELISA value and was added in duplicate to ELISA wells
(as per our normal ELISA, see above) and incubated overnight at
4uC followed by washing and addition of 20 mM phosphate buffer
to one well or 20 mM phosphate buffer containing 3 M
ammonium thiocyanate (SIGMA, Cat. 431354) to another well
followed by incubation for 15 minutes at room temperature.
Following the room temperature incubation, ELISA wells were
washed followed by the addition of goat anti-rabbit Ig-alkaline
phosphatase (Southern Biotech, Birmingham, AL) and the assay
completed as per our normal ELISA protocol. The ELISA raw
data values for each sample were used to calculate the percent
antibody remaining bound in the presence of 3 M ammonium
thiocyanate as compared to phosphate buffer (i.e., 0 M ammoni-
um thiocyanate).
BoNT/A neutralization assay
A serum neutralization assay was utilized with modifications
from that described by others [32] to test serum for its ability to
neutralize BoNT/A. Sera were collected from Dutch Belted
rabbits on days 41 and 105. Individual serum samples were diluted
to the desired dilution to produce a final volume of diluted serum
in 200 ml in PBS with 0.2% gelatin (SIGMA, St. Louis, MO). To
the 200 ml of diluted serum was added 200 ml PBS/gelatin
containing 20 LD50 Botulinum Neurotoxin A (Metabiologics,
Madison, Wisconsin). The serum and toxin mixture were
incubated at room temperature for 1 hour before 200 ml of the
mixture (containing 10 LD50 BoNT/A) was injected intraperito-
neally into naı ¨ve, female BALB/c mice. Mice were monitored
after 2 and 6 hours and then daily for signs of morbidity, including
difficulty breathing and lack of mobility. Mice exhibiting
morbidity were euthanized with Duke IACUC approved methods.
Statistical Analysis
Log2 ELISA antibody titers and BoNT/A neutralization titers
were compared by ANOVA, followed by Tukey’s multiple
comparison method. The Mann-Whitney test was used to
compare neutralizing antibody titers grouped by antigen (Hcbtre
+ adjuvant vs Hcbre-Ad2F + adjuvant) to determine if their were
significant differences between adjuvanted Hcbtre or Hcbtre-
Ad2F in their ability to induce BoNT/A neutralizing antibody.
The Mann-Whitney test was also used to compare antibody
avidity (% antibody bound in the presence of 3 M ammonium
thiocyanate) between serum with no BoNT/A neutralization
activity and serum with detectable BoNT/A neutralization
activity. Significant differences were defined as p,0.05.
Results
Ad2F enhances the immunogenicity of BoNT/A Hcbtre in
New Zealand White rabbits after intranasal immunization
with cholera toxin or the mast cell activator adjuvant
compound 48/80
Our previous study [7] demonstrated that a fusion protein
consisting of the botulinum neurotoxin A Hcbtre domain and the
adenovirus type 2 fiber protein (Hcbtre-Ad2F; Figure 1)
exhibited immunogenicity that was superior to that observed for
Hcbtre when both were used as nasal vaccine immunogens. To
determine if Hcbtre-Ad2F exhibited immunogenicity superior to
Hcbtre after nasal delivery to a host with a nasal cavity similar to
humans [13,14], immunogenicity studies were performed in
rabbits. This study was also performed to evaluate the ability of
a novel class of vaccine adjuvants, mast cell activators [17,18] to
provide adjuvant activity in rabbits. Female New Zealand White
rabbits (3–6 rabbits per group) were nasally immunized on days 0,
Mucosally Targeted Botulinum Vaccine
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(20 mg) alone or combined with the adjuvants, CT (2 mg) or C48/
80 (120 mg). To compare the immunogenicity and antigenicity of
the Hcbtre immunogens to other forms of BoNT/A immunogens,
BoNT/A toxoid and BoNT/A Hc were used as control
immunogens. Rabbits were immunized with BoNT/A toxoid
(10 mg) + alum intramuscularly on days 0, 14 and 28 while BoNT/
A Hc (20 mg) combined with CT (2 mg) or C48/80 (120 mg) was
delivered nasally on days 0, 14 and 28. Serum was collected on
days 0, 28 and 40 and tested for IgG specific for BoNT/A toxoid,
recombinant BoNT/A Hc or the b-trefoil domain of BoNT/A Hc
(Hcbtre) (Figure 1). Serum titers were calculated and reported as
endpoint geometric means for each group.
Nasal immunization with Hcbtre-Ad2F immunogens formulat-
ed with CT or C48/80 as adjuvants induced the highest serum
anti-Hcbtre IgG titers at Day 27 and Day 40 (Figure 2). At Day
27, nasal immunization with Hcbtre-Ad2F + CT induced a serum
anti-BoNT/A btre IgG titer of 1:11,585 while nasal immunization
with Hcbtre-Ad2F + C48/80 induced a serum anti-BoNT/A
Hcbtre IgG titer of 1:813; the only groups with serum anti-Hcbtre
significantly greater than those induced by other vaccines
(Figure 2). Despite nasal immunization with an equimolar dose
of Hcbtre adjuvanted with CT or C48/80, Hcbtre immunogens
failed to induce significantly elevated serum anti-BoNT/A IgG
titers (Figure 2). Nasal immunization with recombinant BoNT/A
Hc adjuvanted with CT or C48/80 also failed to induce
significantly elevated serum anti-BoNT/A Hcbtre IgG titers. Of
particular interest was the observation that intramuscular
immunization with BoNT/A toxoid adjuvanted with alum failed
to induce serum IgG antibodies that recognized the BoNT/A
Hcbtre domain (Figure 2). Similar results were observed at day
40 with serum anti-BoNT/A Hcbtre IgG titers of 1:524,288 and
1:49,097 for rabbits nasally immunized with Hcbtre-Ad2F + CT
or C48/80, respectively. Serum titers induced by C48/80 were not
significantly different than those induced by CT. Our results
demonstrate that Hcbtre-Ad2F, an immunogen designed to
contain a mucosal targeting component, provided nasal immuno-
genicity that was superior to immunogens lacking the mucosal
targeting domain. Additionally, the mast cell activator C48/80
provided significant adjuvant activity after nasal delivery to
rabbits.
Recombinant BoNT/A Hc immunogens are currently in
development as next generation BoNT vaccines [5,33]. Despite
the lack of immunogenicity of Hc when used as a nasal vaccine, as
measured by the induction of anti-Hcbtre IgG titers, it is possible
that Hc immunogens induce antibodies that recognize epitopes
outside of the Hcbtre domain. We therefore tested day 40 serum
collected from the rabbit groups described in Figure 2 for the
presence of anti-BoNT/A Hc antibodies by ELISA (Figure 3A).
The anti-BoNT/A Hc serum IgG titers at day 40 were similar to
the anti-BoNT/A Hcbtre IgG responses with the highest anti-
Hcbtre IgG titers in rabbits immunized intranasally with Hcbtre-
Ad2F + CT (1:23,170) or Hcbtre-Ad2F + C48/80 (1:4,598). Due
to the variability of the anti-BoNT/A Hc antibody responses,
there were no significant differences between any of the groups.
These results support the findings discussed in Figure 2 and
demonstrate that nasal immunization with Hcbtre-Ad2F immu-
nogens and adjuvant (CT or C48/80) induced maximal anti-
BoNT/A Hc antibody responses that were at least 10-fold greater
than antibody responses induced by any other vaccine group
tested.
Since the current investigational vaccine for botulinum
neurotoxin is a toxoid [5,33] and the toxoid may be antigenically
distinct from the recombinant immunogens [34,35], day 40 serum
samples were also tested for the presence of antibodies that
recognize BoNT/A toxoid (Figure 3B). As expected, intramus-
Figure 2. Ad2 fiber protein enhances the nasal immunogenicity of BoNT/A b-trefoil in NZW rabbits. Female NZW rabbits were
immunized on days 0, 14 and 28 with the indicated vaccine formulation. Intramuscular immunization with 10 mg of BoNT/A toxoid combined with
alum (n=4) served as a control. BoNT/A Hcbtre (10 mg) was nasally delivered in the absence of adjuvant (n=5) or combined with CT (2 mg; n=6) or
C48/80 (120 mg; n=6). BoNT/A Hcbtre-Ad2F (20 mg) was delivered nasally in the absence of adjuvant (n=5) or combined with CT (2 mg; n=6) or C48/
80 (120 mg; n=6). BoNT/A Hc (20 mg) was delivered nasally combined with CT (2 mg; n=3) or C48/80 (120 mg; n=3). Serum samples collected on day
27 and day 40 were tested for the presence of anti-BoNT/A b-trefoil IgG by ELISA. Serum antibody titers were compared between groups by ANOVA
followed by Tukey’s multiple comparison test (GraphPad, Prism). a: serum anti-BoNT/A b-trefoil IgG titers significantly greater than those induced by
intramuscular immunization with toxoid, nasal immunization with Hcbtre, nasal immunization with Hcbtre + CT, nasal immunization with Hcbtre +
C48/80, nasal immunization with Hcbtre-Ad2F, nasal immunization with Hc + CT and nasal immunization with Hc + C48/80. b: serum anti-BoNT/A
b-trefoil IgG titers significantly greater than those induced by nasal immunization with Hcbtre + CT and nasal immunization with Hcbtre + C48/80.
c: serum anti-BoNT/A b-trefoil IgG titers significantly greater than those induced by intramuscular immunization with toxoid, nasal immunization with
Hcbtre, nasal immunization with Hcbtre-Ad2F, nasal immunization with Hcbtre + CT, nasal immunization with Hcbtre + C48/80, nasal immunization
with Hc + CT and nasal immunization with Hc + C48/80. d: serum anti-BoNT/A b-trefoil IgG titers significantly greater than those induced by
intramuscular immunization with toxoid, nasal immunization with Hcbtre, nasal immunization with Hcbtre + CT, immunization with Hcbtre + C48/80,
nasal immunization with Hcbtre-Ad2F and nasal immunization with Hc + C48/80.
doi:10.1371/journal.pone.0016532.g002
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significantly increased serum anti-BoNT/A toxoid IgG titers
(1:50,535) that were significantly greater than all other vaccine
groups tested. In agreement with published literature [34,35], our
results demonstrate that the antigenicity of BoNT/A toxoid is
significantly different than recombinant forms of immunogens
since immunization with BoNT/A toxoid induced antibodies able
to recognize toxoid but not BoNT/A Hcbtre or Hc.
Ad2F enhances b-trefoil immunogenicity in Dutch Belted
rabbits after intranasal immunization with cholera toxin
or the mast cell activator adjuvant C48/80
To determine if the superior immunogenicity of Hcbtre-Ad2F
and the adjuvant activity of C48/80 could be confirmed in a
second rabbit strain, we repeated the intranasal immunization
protocol using BoNT/A Hcbtre or Hcbtre-Ad2F 6 CT or
C48/80 in Dutch Belted rabbits. Four rabbits per group were
immunized on days 0, 14, 28 and 91 with the same molar doses of
Hcbtre(10 mg) or Hcbtre-Ad2F(20 mg) alone or combined withCT
(2 mg) or C48/80 (120 mg). Sera collected on days 27, 41 and 105
were evaluated for the presence of b-trefoil specific IgG antibodies
by ELISA (Figure 4). On day 27, the only groups with significantly
increased serum anti-BoNT/A Hcbtre IgG titers were rabbits
nasally immunized with Hcbtre-Ad2F + CT (1:23,170) or Hcbtre-
Ad2F + C48/80 (1:32,768). These results demonstrate that the
addition ofAd2Fasa mucosaltargetingligandwhencombined with
adjuvant (CT or C48/80) enhanced the immunogenicity of the
Hcbtre immunogen and improved the induction of serum anti-
Hcbtre IgG responses after nasal vaccination. The serum anti-
Hcbtre IgG titers induced by nasal immunization with Hcbtre-
Ad2F + C48/80 were significantly greater than titers induced by
nasal immunization with Hcbtre-Ad2F alone (p,0.05) demonstrat-
ing the mucosal adjuvant activity of C48/80 (Figure 4).
The day 41 serum anti-Hcbtre IgG profile (2 weeks after the day
28 booster dose) was similar to the day 27 responses and the only
groups that generated significantly increased serum anti-Hcbtre
IgG titers were Hcbtre-Ad2F + CT (1:623,487) or Hcbtre-Ad2F +
C48/80 (1:185,364). The serum anti-Hcbtre IgG titers induced by
nasal immunization with Hcbtre-Ad2F + CT were significantly
greater than anti-Hcbtre IgG titers induced by nasal immunization
with Hcbtre, Hcbtre + CT, Hcbtre + C48/80 (Figure 4,p ,0.05).
Serum anti-Hcbtre IgG titers induced by nasal immunization with
Hcbtre-Ad2F + C48/80 were significantly greater than anti-
Hcbtre IgG titers induced by nasal immunization with Hcbtre or
Hcbtre + C48/80 (Figure 4,p ,0.05). For each vaccine
formulation tested (i.e., antigen alone, antigen + CT or antigen
+ C48/80), the presence of the Ad2F domain increased the
induction of serum anti-Hcbtre IgG antibody titers. For example,
nasal immunization with Hcbtre alone induced a serum anti-
Hcbtre IgG titer of 1:76 while nasal immunization with Hcbtre-
Ad2F induced a serum titer of 1:11,585. When administered with
CT, nasal Hcbtre induced a serum titer of 1:2,048 while nasal
immunization with CT and Hcbtre-Ad2F induced a serum titer of
1:623,487. Finally, when administered with C48/80, nasal
immunization with Hcbtre induced a serum anti-Hcbtre IgG titer
of 1:108 while nasal immunization with Hcbtre-Ad2F induced a
serum titer of 1:185,364. Our results demonstrate that the
presence of Ad2F greatly enhanced the immunogenicity of Hcbtre
when used as a nasal vaccine immunogen.
Serum collected on day 105 and tested for the presence of anti-
Hcbtre IgG titers demonstrated that the anti-Hcbtre IgG titers had
increased in all groups although the serum titers induced by nasal
immunization with Hcbtre-Ad2F adjuvanted with CT or C48/80
remained the highest (1:524,288 and 1:131,072, respectively).
Ad2F as a mucosal targeting ligand enhances the
induction of BoNT/A neutralizing antibodies after nasal
immunization with Hcbtre immunogens
We sought to determine whether the antibodies generated by
our Hcbtre vaccines could protect against BoNT/A toxin
challenge and whether the addition of Ad2F enhanced the
induction of BoNT/A neutralizing antibodies. A mouse neutral-
ization assay [32] was used to measure BoNT/A neutralizing
antibodies in day 41 serum (after three doses of vaccine). None of
Figure 3. BoNT/A Hcbtre immunogens induce antibodies that recognize epitopes distinct from those induced by BoNT/A toxoid.
Day 40 sera from a subset of rabbits included in Figure 1 were tested for the presence of antibodies specific for BoNT/A Hc or BoNT/A toxoid by ELISA.
a: serum anti-BoNT/A toxoid IgG titers significantly greater than those induced by all other groups. There were no other significant differences
between groups.
doi:10.1371/journal.pone.0016532.g003
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day 41(data not shown).
Serum collected on day 105 (after a total of 4 vaccinations) was also
tested for the presence of BoNT/A neutralizing antibodies. One rabbit
nasally immunized with Hcbtre + CT had measurable BoNT/A
neutralizing antibodies (titer of 1:8) while all other rabbits in that group
and none of the rabbits nasally immunized with Hcbtre, Hcbtre +
C48/80 or Hcbtre-Ad2F had measurable serum BoNT/A neutraliz-
ing antibodies. Rabbits nasally immunized with Hcbtre-Ad2F + CT
had a geometric mean serum BoNT/A neutralizing titer of 1:45.25
while rabbits nasally immunized with Hcbtre-Ad2F + C48/80 had a
serum BoNT/A neutralizing titer of 1:26.91 (Figure 5A). Serum
BoNT/A neutralizing antibody titers induced by nasal immunization
with Hcbtre-Ad2F + CT or Hcbtre-Ad2F + C48/80 were significantly
greater than the neutralizing antibody titers measured in rabbits nasally
immunized with Hcbtre, Hcbtre + CT, Hcbtre + C48/80 or Hcbtre-
Ad2F; ANOVA and Tukey’s multiple comparison (Figure 5A,
p,0.05). By combining serum BoNT/A neutralizing antibody titers
induced by nasal immunization with Hcbtre + CT or C48/80
(Figure 5B,H c btre + adjuvants) and comparing their serum
neutralization titer to those induced by nasal immunization with
Hcbtre-Ad2F + CT or C48/80 (Figure 5B,H c btre-Ad2F +
adjuvants), we determined that the presence of Ad2F significantly
improved the induction of BoNT/A neutralizing antibodies
(p=0.0006), regardless of the adjuvant used. These results demonstrate
that the use of Ad2F as a mucosal targeting ligand as well as the use of
adjuvant (CT or C48/80) was required for effective induction of serum
BoNT/A neutralizing antibody responses. Additionally, C48/80
provided effective nasal adjuvant activity in rabbits that was
comparable to that provided by CT.
Antibody affinity correlates with protective immunity
The binding avidity of antibodies for their antigen may
influence their neutralization capacity [36-38]. To determine if
antibody affinity for Hcbtre correlated with its neutralization
activity, we measured the relative avidity of serum anti-Hcbtre Ig
using a thiocyanate elution ELISA similar to that described by
others [29–31]. In this assay, the amount of antigen-specific
antibody remaining bound in the presence of 3 M ammonium
thiocyanate, calculated as a percentage of antibody bound in the
absence of ammonium thiocyante, is used to estimate the relative
avidity of the antibodies. The percentage of antibody remaining
bound in the presence of 3 M ammonium thiocyanate increases as
the avidity of the antibody increases. The relative avidity of anti-
Hcbtre Ig in Day 162 serum was tested for all samples that had
measurable anti-Hcbtre serum antibodies (Figure 6). Due to the
variation in the relative avidities measured in the various groups,
there was no significant difference in antibody avidity between the
different groups (Figure 6A). However, grouping of the serum
samples based on their neutralization capacity demonstrated that
serum samples with BoNT/A neutralization activity had an anti-
Hcbtre Ig relative avidity that was greater than that in samples
without BoNT/A neutralization activity (p=0.0239; Figure 6B).
Discussion
In this study we have demonstrated that the b-trefoil domain of
BoNT/A (Hcbtre) can be used as an immunogen for nasal
vaccination in rabbits to induce serum antibodies that protect
against BoNT/A challenge. Our results show that production of
the Hcbtre immunogen as a fusion protein with the mucosal
targeting ligand, Ad2F, enhanced its immunogenicity and the
induction of Hcbtre-specific, BoNT/A-neutralizing antibodies.
Additionally, the mast cell activator adjuvant C48/80 was as
effective as CT for the induction of BoNT/A-neutralizing
antibodies when used as a nasal vaccine adjuvant in rabbits.
These results confirm similar observations in mice [7,17].
Adjuvants and vaccination regimens suitable for nasal immu-
nization are desirable for a number of reasons. First, one goal of
the World Health Organization is to have vaccines administered
needle-free [39–43], such as nasal immunization, since the re-use
Figure 4. Ad2 fiber protein enhances the nasal immunogenicity of BoNT/A b-trefoil in Dutch Belted rabbits. Female Dutch Belted
rabbits (4 per group) were nasally immunized on days 0, 14, 28 and 91 with the indicated vaccine formulation. Serum collected on days 27, 41 and
105 was tested for the presence of anti-BoNT/A b-trefoil IgG by ELISA. a: serum anti-BoNT/A b-trefoil IgG titers significantly greater than those
induced by nasal immunization with Hcbtre or nasal immunization with Hcbtre + C48/80. b: serum anti-BoNT/A b-trefoil IgG titers significantly greater
than those induced by nasal immunization with Hcbtre, nasal immunization with Hcbtre + C48/80 or nasal immunization with Hcbtre-Ad2F. c: serum
anti-BoNT/A b-trefoil IgG titers significantly greater than those induced by nasal immunization with Hcbtre, nasal immunization with Hcbtre + CT,
nasal immunization with Hcbtre + C48/80. d: serum anti-BoNT/A b-trefoil IgG titers significantly greater than those induced by nasal immunization
with Hcbtre or nasal immunization with Hcbtre + C48/80. e: serum anti-BoNT/A b-trefoil IgG titers significantly greater than those induced by nasal
immunization with Hcbtre.
doi:10.1371/journal.pone.0016532.g004
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of infectious diseases. Second, nasal immunization offers a
beneficial alternative for patients with needle-phobia and may
prevent their avoidance to vaccination [44–46]. Third, nasal
immunization has the ability to induce antigen-specific secretory
IgA (S-IgA) responses in mucosal secretions, while parenterally
delivered vaccines rarely induce S-IgA [47–49]. A major benefit of
mucosal immunization is the presence of pathogen-specific S-IgA
in mucosal secretions offering an added layer of protection against
pathogens that primarily infect via a mucosal surface. Such
capacity to induce vaccine-specific S-IgA as well as the ease of
needle-free immunization warrants continued research to optimize
adjuvants and antigen formulations for nasal subunit vaccines.
The form of antigen used as a vaccine immunogen significantly
influences the immune responses induced. To evaluate the
performance of Hcbt r ei m m u n o g e n sa sc o m p a r e dt oo t h e rB o N T /
A immunogens, we utilized BoNT/A toxoid and BoNT/A Hc
immunogens as controls for subcutaneous or intranasal immuniza-
tion, respectively. Of all immunogens tested, only Hcbtre-Ad2F
combined with adjuvant (CT or C48/80) induced significantly
Figure 5. Ad2 fiber protein enhances the induction of BoNT/A-neutralizing antibodies in nasally immunized rabbits. Female Dutch
Belted rabbits (4 per group) were nasally immunized on days 0, 14, 28 and 91 with the indicated vaccine formulation. A. Serum collected on day 105
was tested for the presence of BoNT/A-neutralizing antibodies using a mouse neutralization assay. a: serum BoNT/A-neutralizing activity significantly
greater than the neutralizing activity measured in rabbits nasally immunized with Hcbtre, Hcbtre + CT, Hcbtre + C48/80 or Hcbtre-Ad2F; ANOVA and
Tukey’s multiple comparison, p,0.05. b: serum BoNT/A-neutralizing activity significantly greater than the neutralizing activity measured in rabbits
nasally immunized with Hcbtre, Hcbtre + CT, Hcbtre + C48/80 or Hcbtre-Ad2F; ANOVA and Tukey’s multiple comparison, p,0.05. B.H c btre-Ad2F is
superior to Hcbtre for the induction of BoNT/A neutralizing antibodies when delivered with CT or C48/80 as adjuvants. a: p=0.0006, Mann-Whitney
test.
doi:10.1371/journal.pone.0016532.g005
Figure 6. Adjuvants enhance the avidity of anti-BoNT/A b-trefoil IgG antibodies. The relative avidity of anti-BoNT/A IgG serum antibodies
was measured using day 162 serum using a modified ELISA as described in Materials and Methods. A. The percent antibody bound in the ELISA in the
presence of 3 M ammonium thiocyanate is indicated for individual serum samples that had measurable anti-b-trefoil IgG. A higher percent antibody
bound represents a greater relative avidity for vaccine-induced, antigen-specific antibody.N: represents serum anti-b-trefoil IgG with no detectable
BoNT/A neutralizing activity. #: represents serum anti-b-trefoil IgG with detectable BoNT/A neutralizing activity. B. Average percent antibody bound
when samples were organized by the neutralization capacity of the serum. Vaccine-induced BoNT/A neutralizing antibody has significantly greater
avidity than non-neutralizing antibody. a: % antibody bound significantly greater than in the no neutralization group. Two-tailed Mann Whitney,
p=0.0239.
doi:10.1371/journal.pone.0016532.g006
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an immunogen at the same dose as Hcbtre-Ad2F and formulated
with CT or C48/80 as adjuvants, Hc did not induce significantly
elevated serum anti-Hcbtre or anti-Hc IgG titers, even though the
Hcbtre domain represents a significant portion of the Hc
immunogen. BoNT/A toxoid delivered intramuscularly with
alum induced significantly elevated serum anti-BoNT/A toxoid
IgG antibodies while inducing minimal serum IgG antibodies
specific for Hcbtre or Hc. This result confirms published
reports describing the altered antigenicity of BoNT/A toxoid as
compared to native immunogens [34,35] and supports the use of
recombinant subunit immunogens as next generation BoNT
vaccines.
The immunization regimens utilized in this study used relatively
low antigen doses. We selected a dose of 10 mgo fH c btre per
vaccination and an equimolar dose of 20 mgH c btre-Ad2F to
increase the sensitivity of the experiment to determine if the use of
the mucosal targeting ligand Ad2F was able to significantly
enhance the immunogenicity of Hcbtre. In our previous mouse
study, Hcbtre-Ad2F exhibited superior nasal immunogenicity
when compared to Hcbtre based on the induction of ELISA
binding antibodies but both immunogens induced BoNT/A
neutralizing antibody responses when used at 25 mgo fH c btre
per dose and 50 mgo fH c btre-Ad2F per dose [7]. In the present
study, nasal immunization with Hcbtre-Ad2F adjuvanted with CT
or C48/80 induced serum neutralization titers in Dutch belted
rabbits that ranged from 1:16 to 1:128 with each rabbit being
immunized with a total of 80 mgo fH c btre-Ad2F combined with
adjuvant. The neutralization assay tested diluted serum for its
ability to neutralize 10 LD50 of BoNT/A using a mouse
neutralization assay. Others have reported that immunization of
rabbits intradermally with a total dose 750 mg of BoNT/A Hc
(residues 871-1295) adjuvanted with complete (priming) and
incomplete (booster doses) Freund’s adjuvant in five doses induced
serum BoNT/A neutralizing antibodies with a neutralization
capacity that ranged from 5610
5 to 7610
5 mouse LD50 per mL
serum [32]. Given in these terms, our adjuvanted Hcbtre-Ad2F
vaccine exhibited a BoNT/A neutralization capacity ranging from
1.6610
3 to 1.28610
4 mouse LD50 per ml of serum while using
only 80 mg of total antigen and nasal delivery. One rabbit
immunized with a Hcbtre and CT had a serum BoNT/A
neutralization capacity of 800 mouse LD50 per ml of serum
demonstrating the ability of Hcbtre to induce BoNT/A neutral-
izing antibodies. Our use of higher doses of Hcbtre or Hcbtre-
Ad2F would likely have induced more potent BoNT/A neutral-
izing antibody responses.
The exact mechanism utilized by Ad2F to augment the
immunogenicity of nasally-delivered Hcbtre is not clear. We
originally selected Ad2F as a mucosal targeting ligand and
demonstrated its ability to mediate antigen binding at the
epithelial surface in the mouse nasal cavity [7]. Therefore, it is
possible that Hcbtre-Ad2F immunogens bind to the epithelial
surface after nasal delivery to rabbits resulting in enhanced antigen
retention within the nasal cavity allowing more antigen to be
available for induction of Hcbtre-specific immune responses. This
conclusion is supported by recent studies in our group demon-
strating that nasal vaccination regimens in rabbits that enhance
retention of the vaccine within the nasal cavity enhance the
induction of antigen-specific serum antibodies [50]. Studies in the
mouse that demonstrate superior induction of BoNT/A neutral-
izing antibodies when using vaccine formulations that result in
continued adherence of the vaccine to the nasal epithelium also
support this conclusion [51]. Although antigen retention within
the nasal cavity may contribute to the enhanced immunogenicity
of Hcbtre-Ad2F immunogens, the ability of Ad2F to induce
cytokine and chemokine expression after binding to its receptor,
the coxsackie-adenovirus receptor (CAR), may also contribute to
the superior immunogenicity of Hcbtre-Ad2F [52].
Induction of BoNT/A-neutralizing antibodies required the use
of an adjuvant. We utilized CT as a classic mucosal vaccine
adjuvant to determine if the mast cell activator C48/80 [17]
provided effective adjuvant activity in the rabbit comparable to
that provided by CT. C48/80 provided effective adjuvant activity
that was comparable to that provided by CT after nasal
immunization with Hcbtre-Ad2F. We have previously reported
the C48/80 provided effective adjuvant activity in mice while not
inducing antigen-specific IgE responses or other adverse effects
such as induction of anaphylactic reactions [17,18]. Although
antigen-specific IgE responses were not monitored in this rabbit
study, the use of C48/80 was not associated with the induction of
adverse effects such as immediate immunization site reactions or
hypersensitivity reactions. While additional studies are needed to
thoroughly evaluate the preclinical toxicity of C48/80, no adverse
effects have been observed to date. Our results are the first to
demonstrate that mast cell activators provide safe and effective
mucosal vaccine adjuvant activity in rabbits.
Many factors such as antibody concentration, specificity and
avidity may contribute to the biological activity of vaccine-induced
antibodies. Attempts at mapping linear epitopes recognized by
Hcbtre and Hcbtre-Ad2F vaccine-induced antibodies were
unsuccessful (data not shown) suggesting that the antibodies
induced by the Hcbtre immunogens recognize conformational
epitopes. By measuring the relative avidity of anti-Hcbtre serum Ig
with the use of a modified ELISA [29–31] that tests serum at
similar antibody concentrations, we determined that serum
samples with BoNT/A neutralization activity exhibited a relative
binding avidity that was significantly higher than the relative
avidity of non-neutralizing antibodies. Our results are in
agreement with observations that the biological activity of
antibodies is positively correlated with their binding avidity for
their specific antigen [37,38,53–55]. Induction of high avidity,
BoNT/A-neutralizing antibodies required the use of adjuvants
(CT or C48/80) and future studies will work to optimize vaccine
formulations and adjuvants for their ability to induce high-avidity
antibodies.
Nasal immunization with Hcbtre or Hcbtre-Ad2F in Dutch
belted rabbits induced minimal vaginal or fecal anti-Hcbtre IgA
responses (data not shown). Although we have demonstrated in
mouse models that nasal vaccination is an effective method of
immunization for the induction of antigen-specific mucosal IgA
[7,50,56–59], our nasal immunization studies in non-human
primates [59,60] and rabbits [50] have failed to consistently induce
mucosal IgA responses in fecal samples or vaginal secretions. Our
results in rabbits are supported by published reports from others
that also failed to induce significant mucosal IgA responses after
nasal immunization [61,62]. Our use of low antigen doses may
have contributed to the poor induction of mucosal IgA in rabbits
after nasal immunization with Hcbtre immunogens since antigen
dose has been demonstrated to influence the induction of mucosal
IgA responses after nasal immunization [63]. Collectively, these
results suggest that the conditions required for induction of
mucosal IgA in non-rodents requires further studies.
While the live-attenuated influenza vaccine (LAIV) provides a
convincing example that nasally-administered vaccines may be
approved by the U.S. Food and Drug Administration (FDA) and
are able to safely induce the desired immune responses in humans
[64–66], additional pre-clinical studies are needed to develop nasal
subunit vaccines for use in humans. For example, the potential for
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when considering the development of nasally-administered
vaccines for use in humans since murine nasal immunization
studies have demonstrated the induction of antigen-specific IgE
and airway inflammation when potent adjuvants such as cholera
toxin are used [22,67]. Clear advantages of using our vaccine
formulation are the lack of vaccine-induced IgE or anaphylactic
reactions by C48/80 when used as a nasal vaccine adjuvant in
mice [17] and the lack of sensitivity reactions in rabbits. To avoid
potential lung inflammation, nasal immunization methods must
include in its design a means to retain the vaccine in the nares,
while simultaneously preventing subsequent deposition into the
lungs. This can be accomplished by limiting the vaccine to the
upper respiratory tract by nasal sprays that deliver large droplets
[67] or the use of dry powder vaccine formulations with large
particles (i.e., approximately 10 mm) that are directed only to the
upper respiratory tract and unable to reach the lung [68]. Since
humans are repeatedly exposed to natural upper respiratory tract
infections that induce inflammation and antigen-specific immune
responses with no obvious deleterious effects to the host, it seems
unlikely that adjuvant-dependent or antigen-specific immune
responses induced by nasal immunization would initiate adverse
effects in the host. Additional preclinical studies are needed to
evaluate the safety and toxicity of nasally-delivered subunit
vaccines.
To summarize, recombinant BoNT/A immunogens utilizing
the Hcbtre domain are effective immunogens that contain BoNT/
A neutralizing epitopes. When expressed as a fusion protein with
Hcbtre, the mucosal targeting ligand Ad2F significantly improved
the nasal immunogenicity of Hcbtre and enhanced the induction
of BoNT/A neutralizing antibodies with increased avidity when
delivered with adjuvants. The chemical mast cell activator C48/80
provided adjuvant activity for nasally administered Hcbtre-Ad2F
that was comparable to the adjuvant activity of cholera toxin.
Collectively, our results suggest that the use of the mucosal
targeting ligand Ad2F and the novel adjuvant C48/80 are effective
methods to augment the immunogenicity of nasally-delivered
subunit immunogens for the induction of antibodies with increased
avidity and biological activity.
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